Atara Biotherapeutics, Inc. (ATRA) Q3 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to the ATARA Biotherapeutics Q3 2020 Financial Results Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Eric Heilengren, VP of Investor Relations and Finance of ATARA Therapeutics. Thank you, please go ahead, sir. Thank you, operator. Good afternoon, everyone, and welcome to ATARA's third quarter 2020 conference call. On today's call, members from the ATARA executive team will provide an update on our financial results and operational progress, and also review our upcoming key milestones and objectives. Earlier today, we issued a press release announcing our third quarter 2020 financial results and operational progress. This press release and an updated investor presentation are available in the Investor and Media section at atarabio.com. Joining me on today's call are Dr. Pascal Tuchon, President and Chief Executive Officer, Dr. Jacob DuPont, Executive Vice President and Global Head of Research and Development, Upal Kopikar, Chief Financial Officer, Joe Newell, Chief Operations Officer, Dr. A.J. Joshi, Chief Medical Officer, and Kristen Urema, Chief Commercial Officer. We will begin with prepared comments from Pascal and Jacob, and then open up the call for your questions. We would like to remind listeners that during the call, the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to ri...